Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
Purpose The objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Patients and Methods Chemonaive patients with stage IIIB-IV NSCLC received either vinoelbine 30 mg/m 2 (day...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2008-01-01
|
| Series: | Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine |
| Online Access: | https://doi.org/10.4137/CCRPM.S578 |
| _version_ | 1828491990580330496 |
|---|---|
| author | Sevket Ozkaya Serhat Findik Oguz Uzun Atilla Guven Atici Levent Erkan |
| author_facet | Sevket Ozkaya Serhat Findik Oguz Uzun Atilla Guven Atici Levent Erkan |
| author_sort | Sevket Ozkaya |
| collection | DOAJ |
| description | Purpose The objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Patients and Methods Chemonaive patients with stage IIIB-IV NSCLC received either vinoelbine 30 mg/m 2 (days 1 and 8) plus cisplatin 80 mg/m 2 (day 1) every 21 days (VC arm) or gemcitabine 1250 mg/m 2 (days 1 and 8) plus cisplatin 80 mg/m 2 (day 1) every 21 days (GC arm). Results One hundred thirtyfour patients (67 VC and 67 GC) were included to the study. Overall response rates for the VC arm (31.2%) were not significantly different from that of the GC arm (34.3%). There were no differences in overall survival and one-year survival rates. Median survival and one-year survival rates for the VC and GC groups were 10.6 and 11.5 months, 45% and 46.8%, respectively. Grade 3-4 thrombocytopenia was significantly higher on the GC arm (VC 1.4% v GC 8.9%, p < 0.05), as was febrile neutropenia on the VC arm (VC 8.9% v GC 1.4%, p < 0.05). Conclusion VC and GC demonstrated similar efficacy but there were differences in toxicity profiles. |
| first_indexed | 2024-12-11T11:12:35Z |
| format | Article |
| id | doaj.art-271a000c604743e8b923b427118d01ad |
| institution | Directory Open Access Journal |
| issn | 1179-5484 |
| language | English |
| last_indexed | 2024-12-11T11:12:35Z |
| publishDate | 2008-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine |
| spelling | doaj.art-271a000c604743e8b923b427118d01ad2022-12-22T01:09:28ZengSAGE PublishingClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine1179-54842008-01-01210.4137/CCRPM.S578Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung CancerSevket Ozkaya0Serhat Findik1Oguz Uzun2Atilla Guven Atici3Levent Erkan4Department of Pulmonary Medicine Faculty of Medicine Ondokuz Mayis University SAMSUN/TURKEY.Department of Pulmonary Medicine Faculty of Medicine Ondokuz Mayis University SAMSUN/TURKEY.Department of Pulmonary Medicine Faculty of Medicine Ondokuz Mayis University SAMSUN/TURKEY.Department of Pulmonary Medicine Faculty of Medicine Ondokuz Mayis University SAMSUN/TURKEY.Department of Pulmonary Medicine Faculty of Medicine Ondokuz Mayis University SAMSUN/TURKEY.Purpose The objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Patients and Methods Chemonaive patients with stage IIIB-IV NSCLC received either vinoelbine 30 mg/m 2 (days 1 and 8) plus cisplatin 80 mg/m 2 (day 1) every 21 days (VC arm) or gemcitabine 1250 mg/m 2 (days 1 and 8) plus cisplatin 80 mg/m 2 (day 1) every 21 days (GC arm). Results One hundred thirtyfour patients (67 VC and 67 GC) were included to the study. Overall response rates for the VC arm (31.2%) were not significantly different from that of the GC arm (34.3%). There were no differences in overall survival and one-year survival rates. Median survival and one-year survival rates for the VC and GC groups were 10.6 and 11.5 months, 45% and 46.8%, respectively. Grade 3-4 thrombocytopenia was significantly higher on the GC arm (VC 1.4% v GC 8.9%, p < 0.05), as was febrile neutropenia on the VC arm (VC 8.9% v GC 1.4%, p < 0.05). Conclusion VC and GC demonstrated similar efficacy but there were differences in toxicity profiles.https://doi.org/10.4137/CCRPM.S578 |
| spellingShingle | Sevket Ozkaya Serhat Findik Oguz Uzun Atilla Guven Atici Levent Erkan Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine |
| title | Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer |
| title_full | Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer |
| title_fullStr | Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer |
| title_full_unstemmed | Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer |
| title_short | Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer |
| title_sort | comparison of vinorelbine cisplatin with gemcitabine cisplatin in patients with advanced non small cell lung cancer |
| url | https://doi.org/10.4137/CCRPM.S578 |
| work_keys_str_mv | AT sevketozkaya comparisonofvinorelbinecisplatinwithgemcitabinecisplatininpatientswithadvancednonsmallcelllungcancer AT serhatfindik comparisonofvinorelbinecisplatinwithgemcitabinecisplatininpatientswithadvancednonsmallcelllungcancer AT oguzuzun comparisonofvinorelbinecisplatinwithgemcitabinecisplatininpatientswithadvancednonsmallcelllungcancer AT atillaguvenatici comparisonofvinorelbinecisplatinwithgemcitabinecisplatininpatientswithadvancednonsmallcelllungcancer AT leventerkan comparisonofvinorelbinecisplatinwithgemcitabinecisplatininpatientswithadvancednonsmallcelllungcancer |